Semaglutide diarrhea symptom guide

Semaglutide diarrhea: current Wegovy rates and warning signs

Review diarrhea during semaglutide care using current Wegovy labeling, including the weekly-injection trial rate, tablet evidence limits, hydration and medication questions, and compounded-product distinctions.

Educational guideUpdated August 4, 2026

A label-first response to diarrhea during semaglutide care

Identify the exact product and route: Wegovy injection or tablets, Ozempic injection or tablets, or a patient-specific compounded semaglutide prescription.

Describe stool frequency and consistency, urgency, nighttime symptoms, pain, vomiting, fever, bleeding, food and fluid intake, and urine output.

Record onset, duration, severity, recurrence, and timing relative to treatment, a clinician-directed change, refill, illness, travel, food exposure, or another medicine.

Contact the prescriber before changing treatment or adding an anti-diarrhea medicine, electrolyte product, supplement, or restrictive diet.

Use prompt in-person care for severe abdominal, dehydration, bleeding, allergic, neurologic, or other emergency warning signs.

Direct answer

Diarrhea is a common adverse reaction with semaglutide, but rates are product- and study-specific. In pooled adult weight-management trials in the current Wegovy label, diarrhea occurred in 30% of participants receiving the 2.4 mg once-weekly injection versus 16% receiving placebo. That comparison does not establish a rate for Ozempic, oral Wegovy, or a patient-specific compounded semaglutide prescription. Contact the prescriber for new, persistent, worsening, severe, recurrent, or function-limiting diarrhea, especially with vomiting, poor intake, dizziness, reduced urination, another glucose-lowering medicine, or a recent treatment or product change. Severe or persistent abdominal pain, blood or black stool, repeated vomiting, fainting, confusion, inability to keep fluids down, or serious allergy symptoms needs prompt in-person assessment.

Current label answer

Wegovy weekly-injection trials report diarrhea in 30% versus 16% with placebo

The Wegovy prescribing information updated June 18, 2026 covers both subcutaneous injection and once-daily tablets. In pooled adult weight-management trials of the 2.4 mg once-weekly injection, diarrhea was reported in 30% of Wegovy-treated participants and 16% of participants receiving placebo. The label says the types and frequency of common adverse reactions in the Wegovy 25 mg tablet trial were similar to those in the injection table, but it does not publish a tablet-specific diarrhea percentage there. These data establish a recognized association in the studied population without predicting one person’s cause, severity, or duration.

Keep the 30% versus 16% comparison tied to pooled adult trials of branded Wegovy 2.4 mg weekly injection.
Do not present the injection percentage as a tablet-specific rate or transfer it to Ozempic, another indication or strength, or compounded semaglutide.
A group-level trial percentage cannot determine whether semaglutide caused an individual episode or how long the symptom should last.

Pattern and possible causes

Timing supports a medication review but does not identify the cause by itself

Loose or frequent stools during semaglutide care may follow treatment initiation or a clinician-directed change, but infection, foodborne illness, travel, another medicine, a supplement, pregnancy, an inflammatory or malabsorption condition, and other medical problems can produce a similar pattern. A useful review separates one brief episode from persistent, recurrent, nighttime, bloody, painful, or intake-limiting diarrhea and records what else changed at the same time.

Record stool frequency and consistency, urgency, nighttime symptoms, mucus or blood, abdominal pain, fever, vomiting, sick contacts, travel, food exposure, and recent antibiotics.
Share whether symptoms followed treatment, a refill, product or pharmacy change, illness, another medicine, a supplement, alcohol, or a substantial diet change.
Do not assume every episode is an expected adjustment or use symptom timing alone as proof that semaglutide is the only cause.

Hydration, kidneys, and glucose

Fluid loss and poor intake can change the urgency of diarrhea

Current Wegovy labeling warns about acute kidney injury from volume depletion and notes that most reported events occurred in people with gastrointestinal reactions that led to dehydration. It also warns that hypoglycemia risk can increase when semaglutide is used with insulin or an insulin secretagogue such as a sulfonylurea. Diarrhea alone does not diagnose dehydration, kidney injury, or low blood sugar, so the prescriber needs the full intake, urine, medication, symptom, and monitoring pattern.

Share fluid and food intake, vomiting, urine amount and color, dizziness, fainting, weakness, heat exposure, kidney or heart history, and any fluid restriction.
If glucose monitoring is part of care, record readings with symptoms, meals, activity, alcohol, insulin, sulfonylureas, and other glucose-lowering medicines; follow the individualized response plan.
Do not improvise a medicine hold, catch-up dose, electrolyte recipe, glucose treatment, or anti-diarrhea plan from generic online advice.

Product identity and medication review

The exact semaglutide product and every other medicine matter

Wegovy and Ozempic are FDA-approved finished semaglutide products with product-specific indications, routes, presentations, instructions, and evidence. A patient-specific compounded semaglutide preparation is not an FDA-approved finished drug product and may differ in concentration, inactive ingredients, container, labeling, storage, and beyond-use date. Metformin, antibiotics, magnesium products, laxatives, some supplements, and other medicines may also contribute to diarrhea for some people. The responsible clinician or pharmacist should review the full pattern before the next treatment decision.

Bring the product name, indication, route, strength or concentration, manufacturer or dispensing pharmacy, refill or lot details, storage history, and a photo of the current label.
List every prescription, over-the-counter medicine, vitamin, mineral, laxative, antacid, magnesium product, supplement, alcohol product, and cannabis product.
Contact the prescriber before skipping, repeating, stopping, restarting, splitting, increasing, decreasing, or converting between a tablet and injection.

Escalation and follow-up

Persistent diarrhea and emergency warning signs need different pathways

For non-emergency diarrhea, the prescriber can review the exact product, symptom pattern, hydration, glucose plan, other medicines, and medical history before deciding whether examination, testing, monitoring, supportive care, or a treatment change is appropriate. Severe pain, substantial fluid loss, bleeding, serious allergy symptoms, or neurologic change should not wait for a routine portal reply or the next refill visit.

Contact the prescriber for new, persistent, worsening, severe, recurrent, nighttime, or function-limiting diarrhea; poor intake; reduced urination; symptoms after a refill or clinician-directed change; or uncertainty before the next treatment.
Seek prompt in-person assessment for severe or persistent abdominal pain, blood or black stool, repeated vomiting, inability to keep fluids down, fainting, confusion, severe weakness, marked reduction in urination, or a rigid or markedly swollen abdomen.
Trouble breathing, facial or throat swelling, collapse, or widespread hives with breathing difficulty needs emergency evaluation.

Patient safety checklist

Questions to ask about diarrhea during semaglutide treatment

These points are educational and do not replace medical advice. A licensed clinician should review individual history, medications, risks, and state-specific availability before treatment.

✓

Which exact product and route am I using: Wegovy injection or tablets, Ozempic injection or tablets, or a patient-specific compounded semaglutide prescription?

✓

When did diarrhea begin, how often is it happening, what is the stool consistency, and did it follow treatment, a refill, illness, travel, food exposure, or another medicine?

✓

Can I keep food and fluids down, how often am I urinating, and do I have vomiting, dizziness, fainting, weakness, fever, nighttime symptoms, or meaningful weight change?

✓

Do I have severe or persistent abdominal pain, blood or black stool, marked swelling, confusion, rash, trouble breathing, or facial or throat swelling?

✓

Could metformin, antibiotics, laxatives, magnesium, antacids, supplements, alcohol, or another product contribute to the pattern or change the safest response?

✓

Do kidney or heart disease, diabetes medicines, prior bowel disease or surgery, pregnancy possibility, immune suppression, or a fluid restriction change the plan?

✓

If glucose or blood-pressure monitoring is part of care, which readings and symptoms should trigger same-day guidance or urgent assessment?

✓

Who should I contact before the next treatment or refill, and which symptoms should bypass messaging for urgent or emergency care?

FAQs

Short answers for patients

How common is diarrhea with semaglutide?

Rates depend on the exact product and trial. Current Wegovy labeling reports diarrhea in 30% of participants receiving the 2.4 mg weekly injection versus 16% receiving placebo in pooled adult weight-management trials. That comparison is not a universal rate for every semaglutide product, route, strength, indication, or patient.

How long does semaglutide diarrhea last?

The current Wegovy label does not provide one diarrhea duration for every patient. Record the actual onset, duration, frequency, severity, exact product and route, food and fluid intake, urine output, treatment or refill timing, and other medicines. Contact the prescriber for persistent, severe, recurrent, worsening, nighttime, or intake-limiting symptoms.

Does the Wegovy injection diarrhea rate apply to oral Wegovy?

Not as a tablet-specific percentage. The current label says the types and frequency of common adverse reactions in the Wegovy 25 mg tablet trial were similar to those listed in the injection table, but it does not publish a tablet-specific diarrhea rate there. Route- and product-specific instructions still matter.

Does the Wegovy diarrhea rate apply to compounded semaglutide?

No. A patient-specific compounded preparation is not an FDA-approved finished drug product and may differ in concentration, inactive ingredients, presentation, labeling, storage, and beyond-use date. Wegovy injection trial rates do not establish a diarrhea incidence or product quality for a compounded preparation.

Should I skip semaglutide if I have diarrhea?

Do not skip, repeat, stop, restart, split, or change a semaglutide prescription based on generic online advice. Contact the responsible prescriber with the stool pattern, intake, urine output, other symptoms, medicines, and product details before the next treatment decision. Urgent warning signs require in-person assessment.

Can I take an anti-diarrhea medicine with semaglutide?

Ask the responsible clinician or pharmacist before adding an anti-diarrhea medicine. Fever, blood or black stool, severe abdominal pain, infection risk, pregnancy, heart-rhythm concerns, kidney disease, other medicines, and the cause of diarrhea can change whether a proposed product is appropriate or whether assessment is needed first.

When is diarrhea during semaglutide care urgent?

Seek prompt in-person care for severe or persistent abdominal pain, blood or black stool, repeated vomiting, inability to keep fluids down, fainting, confusion, severe weakness, markedly reduced urination, a rigid or markedly swollen abdomen, trouble breathing, facial or throat swelling, or another serious allergic pattern.

Sources and related reading

Peptide12 pages use conservative educational language and authoritative sources where possible.

DailyMed: Current WEGOVY prescribing information — updated June 18, 2026 MedlinePlus: Semaglutide injection drug information — revised May 15, 2026 MedlinePlus: Diarrhea MedlinePlus: Dehydration FDA: Compounding and the FDA — Questions and Answers FDA MedWatch: Report a serious problem with a medical product Peptide12: Compounded semaglutide injection Peptide12: Wegovy Peptide12: Ozempic Peptide12: GLP-1 diarrhea Peptide12: Semaglutide nausea Peptide12: Semaglutide constipation Peptide12: GLP-1 kidney and dehydration risk Peptide12: When to message your clinician Peptide12: How online peptide therapy works